Medicine carrying table type transdermal nursing method

Abstract

The invention relates to a microneedle transdermal drug delivery technology, in particular to a drug carrying table type transdermal nursing method. The medicine carrying table type transdermal nursing method comprises the following steps: repeatedly touching the skin in a specific area in a reciprocating manner by using a permeation promoting device; performing wetting treatment on the skin in the specific area where the barrier is weakened; repeatedly touching the skin in the specific area for multiple times by using a delivery device so as to deliver the active ingredient; the delivery device comprises a delivery unit, the delivery unit is provided with a medicine carrying platform, and a medicine coating is arranged on the medicine carrying surface of the medicine carrying platform; when the skin in a specific area is touched each time, the medicine coating is partially dissolved, and when the touch frequency reaches a specific frequency, the medicine coating is completely dissolved. The nursing method is easy and convenient to operate, accurate and stable control over the medicine dosage can be achieved, uniform nursing can be conducted on a specific skin area, and meanwhile pausing or stopping can be conducted at any time.

Description

Technical Field

[0001] The invention relates to a microneedle transdermal drug delivery technology, and in particular to a drug-carrying table-type transdermal care method. Background Art

[0002] In the field of transdermal drug delivery technology, chemical transdermal drug delivery has long dominated. In daily life, the method of applying moisturizing cream on the skin is a common transdermal drug delivery technology; another example is plasters in the medical field. However, this method often relies on chemical penetration enhancers to improve the transdermal absorption efficiency of drugs. These chemical penetration enhancers often cause skin discomfort, such as itching, redness, swelling, allergies and other adverse reactions, which greatly affect the patient's experience. In view of this, physical transdermal drug delivery technology came into being. Among physical transdermal drug delivery technologies, microneedle transdermal drug delivery technology has many advantages.

[0003] Microneedle transdermal products are made of metal, single crystal silicon, polymer or other suitable materials, and have a substrate and a microneedle array formed on the substrate. Microneedle transdermal products act on the skin surface through the microneedle array, overcome the skin surface barrier layer and form a dredge channel, so that the active ingredients can be quickly and efficiently absorbed through the skin. In the physical transdermal drug delivery technology, there are many types of transdermal microneedle products, among which the microneedle array on the nanochip has achieved nanometer-level precision, has the advantages of being non-invasive, painless, safe, and efficient, and has won the favor of domestic and foreign experts.

[0004] However, despite the many advantages of microneedle transdermal drug delivery technology, the current implementation methods have many shortcomings. The existing method is usually to apply active ingredients or skin care products on the skin surface, and then use transdermal microneedle products for puncture and dredging. This method faces the following problems in actual operation: First, it is difficult to accurately judge whether the active ingredients applied to the skin surface are completely absorbed, so it is difficult to accurately control the dosage of transdermal drug delivery; second, the residual phenomenon of active ingredients on the skin surface is common, which not only causes the waste of active ingredients, but also may cause unnecessary irritation to the skin; third, the drug delivery progress is not intuitive and convenient enough, making it difficult for patients to understand the treatment progress in real time; fourth, the drug delivery process lacks flexible control means, and it is impossible to realize the need to pause or adjust the drug delivery rate midway.

[0005] In addition, more importantly, many effective ingredients and active substances are not stable in liquid or paste form, and long-term storage can easily lead to reduced activity or ineffectiveness, which further limits the scope of application and promotion of microneedle transdermal drug delivery technology. Especially in the medical field, active ingredients such as insulin, semaglutide, conopeptide, tranexamic acid and hexapeptide are difficult to be compatible with the current microneedle transdermal drug delivery method due to their special requirements for the storage environment, resulting in patients still having to endure the pain and inconvenience brought by traditional injection treatments.

[0006] In the medical field, microneedle transdermal drug delivery technology has spawned a soluble microneedle. The needle body of this type of microneedle is made entirely of soluble materials, and is designed to fall off the substrate and remain in the skin after a single puncture. However, in actual applications, unstable situations such as the needle body failing to fall off effectively, insufficient structural strength failing to effectively puncture the skin, and easy breakage often occur. Even if the needle body has sufficient structural strength, after the first or a few punctures, the needle body will gradually dissolve due to the solubility of the material, resulting in end passivation and loss of puncture ability. Therefore, traditional soluble microneedles are limited to point-of-care drug delivery treatments in very small areas of the skin.

[0007] In summary, the current microneedle transdermal drug delivery technology has defects such as the inability to determine the dosage, drug waste, difficult to control the drug delivery process, difficult to store active substances, and inability to balance the drug delivery. These defects hinder the development of microneedle transdermal drug delivery technology in medical treatment, medical aesthetics, etc., and limit the technological progress of my country's new generation of painless medical care. Summary of the invention

[0008] In order to solve the technical defects of the existing transdermal drug delivery methods, such as the inability to determine the dosage, drug waste, difficult to control the drug delivery process, difficult to store active substances, and inability to balance the drug delivery, the present invention provides a drug-carrying table-type transdermal care method. The drug-carrying table-type transdermal care method comprises the following steps: using a permeation-promoting device to repeatedly touch the skin of a specific area to weaken the skin barrier; the permeation-promoting device comprises a permeation-promoting unit, the permeation-promoting unit has a substrate and permeation-promoting micro-units formed on the substrate; wetting the skin of the specific area whose barrier is weakened; using a delivery device to repeatedly touch the skin of the specific area to deliver the active ingredient; the delivery device comprises a delivery unit, the delivery unit has a drug-carrying platform, and a drug coating is arranged on the drug-carrying surface of the drug-carrying platform, the drug coating is water-soluble and contains the active ingredient; each time the skin of the specific area is touched, the drug coating is partially dissolved, and when the number of touches reaches a specific number, the drug coating is completely dissolved.

[0009] The above technical solution is further explained.

[0010] The penetration-enhancing unit is a transdermal microneedle product in the field of microneedle transdermal drug delivery technology. When the penetration-enhancing unit touches the skin, the penetration-enhancing microunit can puncture the skin, weakening the barrier protection of the skin stratum corneum and improving the transdermal absorption efficiency of the active ingredient. In this technical solution, the penetration-enhancing unit includes a substrate and a penetration-enhancing microunit formed on the substrate. An optional processing technology is to process the substrate surface through a 3D etching process to directly form the penetration-enhancing microunit on the substrate.

[0011] Penetration-enhancing device or delivery device: The penetration-enhancing device or delivery device has a variety of power forms. It can be manually driven or electrically driven. The electric drive mode can be a mechanical transmission device driven by an electric motor or a mechanical transmission device driven by an electromagnetic drive, etc.

[0012] Infiltration unit: In addition to the base and the infiltration microunit, the infiltration unit may also include common parts such as fixing parts, supporting parts, and connecting parts. The infiltration unit can be directly assembled on the infiltration device, or assembled on the infiltration device through these common parts. In addition, the fixing parts and supporting parts can make the assembly of the infiltration unit and the infiltration device more stable and reliable.

[0013] Delivery unit: In addition to the drug loading platform, the delivery unit may also include common components such as fixing components, supporting components, and connectors. The delivery unit can be directly assembled on the delivery device, or assembled to the delivery device through these common components. In addition, the fixing components and supporting components can make the assembly of the delivery unit and the delivery device more stable and reliable.

[0014] Drug coating: The drug coating is solid and attached to the drug-carrying platform of the delivery unit. The drug coating can dissolve in water. Every time the delivery unit touches the skin surface, the drug coating contacts the water on the skin and partially dissolves. Then the drug penetrates into the deep layer of the skin with the water, and the active ingredients are absorbed by the skin. When the contact reaches a certain number of times, the drug coating is completely dissolved and absorbed.

[0015] Wet treatment: In the present technical solution, wet treatment can be carried out in a variety of specific ways, such as cleaning the skin with clean water, applying wet compresses to the skin with wet wipes, spraying water on the skin, atomizing the skin surface, etc.

[0016] The inventive concept of the present invention: This technical solution uses a penetration-promoting device to care for the skin, weaken the skin stratum corneum barrier, and make the skin have a stronger transdermal absorption capacity. The skin microenvironment is changed by moisturizing the skin, so that the skin tissue is more conducive to dissolving and absorbing effective ingredients. On the basis of the above steps, a delivery device is used to care for the skin of a specific area. In this technical solution, active ingredients such as active substances are stored in the delivery device in a solid form, which can maintain activity for a long time and facilitate transportation and storage. The core of the delivery device, the drug-carrying platform, is designed with a unique drug coating structure, which can achieve that each time the skin is touched, a trace amount of drug coating is quickly dissolved in the skin surface moisture, and the effective ingredients carried therewith can be efficiently attached and penetrated into the deep layer of the skin. In particular, when a high-precision mechanical transmission system driven by an electric drive is adopted, the delivery unit can repeatedly contact the skin at a constant and high-frequency rate, and the duration of each touch is precisely controllable, so that the amount of drug coating and effective ingredients dissolved into the skin each time is fixed, thereby achieving accurate quantification of the amount of drug coating and its effective ingredients permeating into the skin.

[0017] Beneficial effects of the present invention: This technical solution uses solid form to store active ingredients. The solid form not only prolongs the active retention period of the active ingredients, but also greatly facilitates transportation and long-term storage needs. During use, the active ingredients are cleverly placed in the drug coating to ensure that they can quickly dissolve and be efficiently absorbed when in contact with skin moisture. This design shortens the exposure time of the active ingredients and effectively maintains their activity. In actual operation, this care method can evenly care for the skin in a specific area, especially when using an electric-driven high-precision mechanical transmission system, the drug dosage can be slowly and controllably released, the dosage is accurate, and the control is stable, which can achieve quantitative, fixed-point, fixed-layer, and fixed-position precise care, greatly improving the accuracy and reliability of the treatment or maintenance process.

[0018] At the user operation level, this care method is easy to operate. The user only needs to touch the care area with the delivery device, without having to worry about the smearing or dripping of the active ingredients, which greatly reduces the difficulty of operation. In addition, the care method also provides a high degree of operational flexibility and interruptibility, allowing the user or caregiver to pause or terminate the care process at any time according to medical guidance or personalized maintenance plans. After the care operation is suspended, the active ingredients remaining in the drug coating can still remain active, and this feature will not cause waste of active ingredients. At the same time, since the remaining active ingredients can be separated from the skin instantly, no new active ingredients will contact the skin or be absorbed by the skin after the care operation is suspended. This feature is particularly important in emergencies such as drug allergies. Therefore, this technical solution also ensures the flexible adjustment capability of the care process.

[0019] In summary, this nursing method can achieve slow and controllable release of active ingredients through intelligent and precise operation design, significantly reduce drug waste, and greatly improve resource utilization efficiency. At the same time, this nursing method simplifies user operation, has high flexibility and interruptibility, and can broaden the prospects for the development of microneedle transdermal drug delivery technology in medical treatment, medical beauty, etc.

[0020] In a preferred technical solution, the specific area includes at least one of the head, face, periorbital area, neck, and hands.

[0021] In a preferred technical solution, the permeation-promoting microunit is made of at least one of single crystal silicon, ceramics, and polymer materials.

[0022] In a preferred technical solution, the end of the permeation-enhancing microunit is conical, pyramidal or knife-edge shaped.

[0023] In a preferred technical solution, the length of the penetration-enhancing microunit is no more than 3000 microns.

[0024] In a preferred technical solution, the diameter of the end of the penetration-promoting microunit is no more than 200 nanometers. In this technical solution, the end of the penetration-promoting microunit reaches the nanometer level, which can achieve painless and non-invasive high-efficiency penetration promotion.

[0025] In the preferred technical solution, the active ingredient includes at least one of finasteride, minoxidil, GLP-1, insulin, semaglutide, conopeptide, tranexamic acid, hexapeptide, salicylic acid, L-vitamin C, retinoic acid, and botulinum toxin. In the preferred technical solution, the drug-carrying table-type transdermal care method can care for the scalp, improve the absorption efficiency of effective active ingredients, stimulate hair follicles and hair regeneration, and bring a more convenient and comfortable treatment experience to patients with hair loss.

[0026] In a preferred technical solution, the content of finasteride is not less than 0.01% and not more than 3%.

[0027] In a preferred technical solution, the content of minoxidil is not less than 0.01% and not more than 5%.

[0028] In a preferred technical solution, the drug-carrying surface is planar. This technical solution provides a delivery unit with a planar drug-carrying surface. The drug coating dissolves when it contacts the moisture on the skin surface, and the active ingredients carried by it are absorbed by the skin.

[0029] In a preferred technical solution, the drug-carrying surface has a delivery microunit, and the drug coating covers the drug-carrying surface and the delivery microunit, or the drug coating only covers the delivery microunit. In this technical solution, the delivery microunit can be a micro-protrusion, micro-needle, or micro-blade structure. This technical solution provides a delivery unit with a protruding structure on the drug-carrying surface. The drug coating covering the delivery microunit can penetrate deeper into the skin, and the drug coating dissolves after contacting the moisture in the skin, and the effective ingredients are efficiently absorbed by the skin.

[0030] In a further preferred technical solution, the penetration-enhancing unit is used to replace the delivery unit, the surface of the substrate forms the drug-carrying surface, the penetration-enhancing microunit replaces the delivery microunit, the drug coating covers the drug-carrying surface and the penetration-enhancing microunit, or the drug coating only covers the penetration-enhancing microunit; the drug-carrying table-type transdermal care method includes the following steps: moisturizing the skin of a specific area; using the penetration-enhancing device to drive the penetration-enhancing unit to perform multiple reciprocating touches on the skin of a specific area; each time the skin of the specific area is touched, the drug coating is partially dissolved, and when the number of touches reaches a specific number, the drug coating is completely dissolved.

[0031] In this preferred technical solution, the penetration-enhancing microunit and the delivery microunit are combined into one. This preferred technical solution is significantly different from the traditional soluble microneedles in terms of product structure, usage, functional effects, etc., which are analyzed in detail below.

[0032] The needle body of a traditional soluble microneedle is made of a soluble material, and its method of use is that after a single puncture, the needle body falls off from the base and remains in the skin. This type of soluble microneedle product can only be used once, and is limited to targeted drug delivery treatment in a very small area of ​​the skin. This type of soluble microneedle has unstable conditions such as the needle body cannot fall off effectively, the needle body structure is not strong enough to effectively puncture the skin, and the needle body is easy to break. It should be noted that the needle body of a traditional soluble microneedle is made of a soluble material. Even if the needle body structure is strong enough to effectively puncture the skin, after the first or a few punctures, the needle body will gradually dissolve, resulting in end passivation. Therefore, the traditional soluble microneedle cannot perform a large number of reciprocating punctures in terms of structural strength and usage scenarios, and its usage scenarios are limited to targeted drug delivery treatment in a very small area of ​​the skin.

[0033] In this preferred technical solution, the penetration-promoting micro-unit uses a solid micro-needle body, which has sufficient structural strength and can puncture the skin efficiently and stably. While the penetration-promoting micro-unit touches the skin and weakens the skin barrier, the drug coating directly contacts the deep layer of the skin, contacts and dissolves with the moisture in the skin, and the active ingredients carried can be efficiently absorbed by the skin. By controlling the dissolution rate of the drug coating, the drug coating can be completely dissolved only after reaching a certain number of times, so that a large range and multiple reciprocating punctures of the skin can be achieved. During the entire care process, the drug coating slowly dissolves and releases, achieving overall and uniform care of the skin. This preferred technical solution further simplifies the operating steps of the care method and facilitates user operation.

[0034] In a further preferred technical solution, the end of the penetration-enhancing microunit has a plurality of tips, the plurality of tips are combined into a cluster, and the drug coating is arranged in the plurality of tips and in the gaps between the tips. In this technical solution, the end of the penetration-enhancing microunit has a plurality of tips, and the structure of these tips increases the adhesion area of ​​the coating exponentially; at the same time, these tips are combined into a cluster to form a drug storage space, and this structure can greatly increase the drug storage capacity of the penetration-enhancing microunit, thereby facilitating large-dose drug delivery.

[0035] In the preferred technical solution, the specific number of times is not less than 100 times and not more than 50,000 times. This preferred technical solution can accurately and quantitatively adjust the dissolution rate of the drug coating by adjusting the number of touches required for the drug coating to completely dissolve. For example, periocular skin care is usually within 30 seconds, so that the drug coating is completely dissolved when it touches the skin 1,000 times. The vibration frequency of the delivery device is selected to be 2,000 times / minute, and the user can complete periocular care within half a minute. At the same time, the active ingredients in the drug coating can be evenly absorbed by the periocular skin. The vibration frequency of the delivery device is usually 1,000-5,000 times / minute. Depending on the specific number of times, the delivery device can be used for tens of seconds to tens of minutes to complete the care of the skin in different positions such as the periocular area, face, and scalp. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 It is a flow chart of Example 1 of the drug-carrying table-type transdermal care method of the present invention.

[0037] Figure 2 It is a schematic diagram of the structure of the penetration-enhancing device in Example 1 of the drug-carrying table-type transdermal care method of the present invention.

[0038] Figure 3 It is a schematic diagram of the structure of the penetration-enhancing unit in the first embodiment of the drug-carrying table-type transdermal care method of the present invention.

[0039] Figure 4 It is a schematic diagram of the structure of the delivery unit in Example 1 of the drug-carrying platform transdermal care method of the present invention.

[0040] Figure 5 It is a schematic diagram of the structure of the delivery unit in the second embodiment of the drug-carrying platform transdermal care method of the present invention.

[0041] Figure 6 It is a flow chart of the third embodiment of the drug-carrying table-type transdermal care method of the present invention.

[0042] Figure 7 It is a schematic diagram of the structure of the penetration-enhancing unit in the third embodiment of the drug-carrying table-type transdermal care method of the present invention.

[0043] Figure 8 It is a schematic diagram of the structure of the penetration-enhancing unit in the fourth embodiment of the drug-carrying table-type transdermal care method of the present invention.

[0044] Fig. 9 It is a schematic diagram of the structure of the penetration-enhancing unit in the fifth embodiment of the drug-carrying table-type transdermal care method of the present invention.

[0045] List of reference numerals: 1. Permeation-enhancing device, 10. Transmission rod, 11. Permeation-enhancing unit, 12. Connector; 111. Base, 112. Permeation-enhancing microunit, 113. Tip, 21. Delivery unit, 211. Drug loading platform, 210. Drug loading surface, 212. Delivery microunit, 22. Drug coating. DETAILED DESCRIPTION

[0046] The present technical solution is further explained and elaborated by some embodiments below. It should be noted that the following embodiments are only used to make the inventive concept and design ideas of the present technical solution clearer and are not used to limit the protection scope of the present invention. It is easy to understand that all other embodiments completed under the guidance of the inventive concept of the present technical solution should also belong to the protection scope of the present invention.

[0047] In order to solve the technical defects of the existing transdermal drug delivery methods, such as the inability to determine the dosage, the waste of drugs, and the difficulty in controlling the drug delivery process, the present invention provides a drug-carrying table-type transdermal care method. The drug-carrying table-type transdermal care method comprises the following steps: step s1: using a permeation-promoting device 1 to touch the skin of a specific area back and forth for many times to weaken the skin barrier; the permeation-promoting device 1 comprises a permeation-promoting unit 11, and the permeation-promoting unit 11 has a substrate 111 and a permeation-promoting micro-unit 112 formed on the substrate 111; step s2: moistening the skin of the specific area whose barrier is weakened; step s3: using a delivery device to touch the skin of the specific area back and forth for many times to deliver the active ingredient; the delivery device comprises a delivery unit 21, and the delivery unit 21 has a drug-carrying platform 211, and a drug coating 22 is arranged on the drug-carrying surface 210 of the drug-carrying platform 211, and the drug coating 22 is water-soluble and contains the active ingredient; each time the skin of the specific area is touched, the drug coating 22 is partially dissolved, and when the number of touches reaches a specific number, the drug coating 22 is completely dissolved.

[0048] In the present technical solution, the specific area may be the head, face, eye area, neck, hand or other suitable part. It is easy to understand that step s1 and step s2 of the above steps may be performed simultaneously, or the operation order of step s1 and step s2 may be interchanged.

[0049] In the present technical solution, the penetration device 1 includes a driving motor, a power supply, a switch, a reciprocating transmission mechanism, and a transmission rod 10, wherein the transmission rod 10 is used to be assembled and connected with the penetration unit 11. The power supply is used to provide electrical energy for the driving motor, and the power supply can be a rechargeable battery, a disposable battery, etc., or it can be powered by a wire connection socket. The driving motor can be an electric motor, and the output shaft of the electric motor is mechanically connected to the reciprocating transmission mechanism. The reciprocating transmission mechanism converts the rotation of the output shaft into reciprocating linear motion and drives the transmission rod 10 and the penetration unit 11 to reciprocate. Alternatively, the driving motor can also be an electromagnetic driver, and the electromagnetic driver controls the transmission rod 10 to drive the penetration unit 11 to reciprocate through the reciprocating transmission mechanism. It is easy to understand that in some scenarios, the penetration device 1 can also be a manual drive device. Similarly, the delivery device in the present technical solution can also include structures such as a motor, a power supply, a switch, a reciprocating transmission mechanism, and a transmission rod. The delivery unit 21 is driven to reciprocate and touch the skin surface manually or electrically.

[0050] In the present technical solution, the penetration unit 11 is directly assembled on the end of the transmission rod 10. It is easy to understand that in order to facilitate the assembly and replacement of the penetration unit 11, the delivery unit may also have a fixing component, a supporting component, a connecting member 12, etc. The penetration unit 11 can be assembled on the transmission rod 10 by connecting members 12 of the type of threads, snaps, etc. The fixing component and the supporting component are in contact with the outer shell of the penetration device 1, so that the delivery unit is more securely assembled and the reciprocating motion is more stable. Similarly, the delivery unit 21 can also be directly assembled or detachably assembled on the delivery device in a similar manner.

[0051] The present technical solution is further described below through several specific embodiments. Embodiment 1

[0052] Figure 1 It is a flow chart of Example 1 of the drug-carrying table-type transdermal care method of the present invention. Figure 2 It is a schematic diagram of the structure of the penetration-enhancing device in Example 1 of the drug-carrying table-type transdermal care method of the present invention. Figure 3 It is a schematic diagram of the structure of the penetration-enhancing unit in the first embodiment of the drug-carrying table-type transdermal care method of the present invention. Figure 4 It is a schematic diagram of the structure of the delivery unit in Example 1 of the drug-carrying platform transdermal care method of the present invention.

[0053] like Figure 2As shown, in the first embodiment, the penetration-enhancing device 1 has a transmission rod 10, which is powered by a driving motor and can reciprocate along its own axis. The penetration-enhancing unit 11 has a connecting piece 12, and the penetration-enhancing unit 11 is detachably assembled on the end of the transmission rod 10 through the connecting piece 12. When the penetration-enhancing unit 11 is driven by the transmission rod 10 to reciprocate along a straight line, it has an upper position and a lower position. The upper position refers to the position where the penetration-enhancing unit 11 moves to the limit outside the shell, and the lower position refers to the position where the penetration-enhancing unit 11 moves to the limit inside the shell. In some embodiments, when the penetration-enhancing unit 11 is in the lower position, the penetration-enhancing unit 11 is completely retracted into the port, that is, the penetration-enhancing unit 11 does not exceed the port. This design can facilitate the user to slide and operate the penetration-enhancing device 1 when caring for the skin.

[0054] like Figure 2 and Figure 3 As shown, in the first embodiment, the penetration-promoting unit 11 includes a substrate 111 and a penetration-promoting micro-unit 112. The substrate 111 is made of materials such as single crystal silicon, metal, ceramic, and polymer. In some processing scenarios, the surface of the substrate 111 is processed by a 3D etching process, a laser engraving process, and a wet etching process, so that the penetration-promoting micro-unit 112 is formed on the surface of the substrate 111. At this time, the material of the penetration-promoting micro-unit 112 is single crystal silicon, metal, ceramic, or polymer material. The penetration-promoting unit 11 in the present technical solution is the transdermal microneedle product in the field of microneedle transdermal drug delivery technology. Preferably, the penetration-promoting unit 11 is a nanochip. When the penetration-promoting unit 11 touches the skin, the penetration-promoting micro-unit 112 can puncture the skin, thereby weakening the barrier protection of the skin stratum corneum and improving the transdermal absorption efficiency of the active ingredients.

[0055] like Figure 3 As shown, in the first embodiment, the penetration-promoting micro-unit 112 is in a cone shape as a whole. Alternatively, the penetration-promoting micro-unit 112 can also be in a prism shape, a cylindrical shape, a pyramid shape, etc., and the end portion thereof is processed to form an end portion that is convenient for puncturing the skin. Figure 3 As shown, the end of the penetration-promoting microunit 112 is conical. Alternatively, the penetration-promoting microunit 112 can also be pyramidal or blade-shaped. In the first embodiment of the present invention, the diameter of the end of the penetration-promoting microunit 112 is not more than 200 nanometers, and the fineness reaches the nanometer level. Optionally, the size of the end is 80 nanometers, which is one thousandth of the diameter of a hair, and the skin can be painlessly and non-invasively treated with efficient penetration. In the first embodiment of the present invention, the length of the penetration-promoting microunit 112 is not more than 3000 microns. In some products, the penetration-promoting microunit 112 is arranged in a rectangular array, a circular array or a honeycomb array on the substrate 111. Optionally, the penetration-promoting microunit 112 is arranged in a square array on the substrate 111 in the manner of 8*8, 7*7, 6*6, 5*5, 4*4, and 3*3.

[0056] like Figures 1 to 3 As shown, in the first embodiment, the skin is cared for by step s1, and the skin of a specific area is repeatedly touched back and forth using the penetration-promoting device 1 to weaken the skin stratum corneum barrier, so that the skin has a stronger transdermal absorption capacity. Afterwards, the skin surface is moistened using an atomizing device, and the operation of step s2 is performed. It is easy to imagine that when performing step s2, the moistening treatment can also have many other specific methods, such as cleaning the skin with clean water, applying wet wipes to the skin, spraying water on the skin, etc., as long as the skin can be kept in a moist microenvironment, the moist microenvironment makes the skin tissue more conducive to dissolving and absorbing the active ingredients. It is easy to understand that steps s1 and s2 can also be performed simultaneously, or the operation order of steps s1 and s2 can be interchanged.

[0057] After completing step s1 and step s2, step s3 is performed: the delivery device is used to repeatedly touch the skin of a specific area to deliver the active ingredient. In step s3 of the first embodiment, the delivery device includes a motor, a power supply, a switch, a reciprocating transmission mechanism, a transmission rod and other structures. The delivery device drives the delivery unit 21 to reciprocate and touch the skin surface by electric means.

[0058] like Figure 4 As shown, the delivery unit 21 has a drug loading platform 211. In the first embodiment, the drug loading platform 211 has a planar drug loading surface 210. A drug coating 22 is coated on the drug loading surface 210. The drug coating 22 is solid and attached to the drug loading surface 210. The drug coating 22 of a specific thickness or a specific dose can be coated on the drug loading surface 210 by spraying, immersion, dripping, dispensing, etc., and the drug coating 22 is solidified by a specific process. The drug coating 22 can be dissolved in water. In the first embodiment, the drug coating 22 contains an active ingredient, which includes at least one of finasteride, minoxidil, GLP-1, insulin, semaglutide, cono peptide, tranexamic acid, hexapeptide, salicylic acid, L-vitamin C, retinoic acid, and botulinum toxin. It is easy to imagine that in some embodiments, the drug coating 22 contains at least one of water, ethanol, hyaluronic acid, isopropanolamine, and isopropanol. When the delivery device drives the delivery unit 21 to touch the skin surface, the drug coating contacts the water on the skin and partially dissolves, and then the drug penetrates into the deep layer of the skin with the water. When the number of touches reaches a certain number, the drug coating 22 is completely dissolved and absorbed. In some embodiments, when the present technical solution is used for scalp hair loss care, the content of finasteride in the active ingredient is not less than 0.01% and not more than 3%. The content of minoxidil is not less than 0.01% and not more than 5%.

[0059] In step s3 of the first embodiment, the vibration frequency of the delivery device is 1000-5000 times / minute. When an electrically driven high-precision mechanical transmission system is used, the time for the drug coating 22 to contact the moisture on the skin surface each time is very short and fixed, so the amount of drug coating 22 dissolved each time is very small and average. In the specific operation process, the skin is cared for in different areas by moving the delivery device, and each touch has a quantitative and trace amount of effective ingredients applied to the skin surface, until the delivery unit 21 touches the skin enough specific times, the drug coating is slowly and evenly completely dissolved. In the first embodiment, the specific number is not less than 100 times and not more than 50,000 times, and further, the specific number is not less than 1000 times and not more than 50,000 times, such as 1000 times, 2000 times, 3000 times, 10,000 times, 30,000 times, 35,000 times, 40,000 times, 45,000 times, etc.

[0060] In the first embodiment, the dissolution rate of the drug coating 22 can be precisely and quantitatively controlled by touching the specific number of times required. Therefore, the technical solution can intuitively and conveniently adjust and control the release and absorption of the active ingredients. At the same time, in the technical solution, the care operation can be suspended at any time. For example, when performing periorbital skin care, the specific number of times is designed to be 1000 times, and the vibration frequency of the delivery device is selected to be 2000 times / minute. That is, the user can perform uniform and repeated massage care on the periorbital skin within half a minute. The user can perform longer care for the eye lines in a specific area according to their own needs. In this embodiment, the user can perform precise point, quantitative, and positioning care on the skin like a smearing operation, and the operation is simple, intuitive, and controllable. When the user needs to suspend care, the drug coating 22 can remain stably stored on the drug-carrying surface 210 of the delivery unit 21, and the active ingredients remaining in the drug coating can still remain active, without causing waste of the active ingredients. When resuming care, the active ingredients in the drug coating can be directly continued to be used, and the overall operation is more convenient. It is worth noting that since the residual active ingredients can be separated from the skin immediately, no new active ingredients will contact the skin or be absorbed by the skin after the care operation is suspended. This feature is particularly important in emergencies such as drug allergies, as it can prevent the skin from being overly irritated or damaged by inappropriate active ingredients.

[0061] It is worth noting that the number of touches required for complete dissolution of the drug coating 22 can be adjusted by adjusting parameters such as the thickness of the drug coating 22 and the difficulty of dissolution. Embodiment 2

[0062] Figure 5 Schematic diagram of the structure of the delivery unit in the second embodiment of the drug-carrying platform transdermal care method of the present invention. Figure 5As shown, different from the first embodiment, in the second embodiment, a delivery microunit 212 is provided on the drug-carrying surface 210 of the drug-carrying platform 211 of the delivery unit 21, that is, the drug-carrying surface 210 is no longer a plane, and its surface has a convex structure. The drug coating 22 is coated on the drug-carrying surface 210 and the delivery microunit 212. In some embodiments, the delivery microunit 212 can be a micro-protrusion, a micro-needle, or a micro-blade structure. The drug coating 22 covering the delivery microunit 212 can penetrate deeper into the skin, and the drug coating 22 dissolves after contacting the moisture in the skin, and the effective ingredients are efficiently absorbed by the skin. It is easy to understand that in some other embodiments, the drug coating 22 can also only cover the delivery microunit 212 without contacting the drug-carrying surface 210. The specific process can be spraying, immersion, dripping, dispensing, etc. Embodiment 3

[0063] Figure 6 It is a flow chart of the third embodiment of the drug-carrying table-type transdermal care method of the present invention. Figure 7 Schematic diagram of the structure of the penetration-enhancing unit in the third embodiment of the drug-carrying platform transdermal care method of the present invention. Figure 6 and Figure 7 As shown, unlike the second embodiment, the third embodiment provides a further simplified technical solution. In the third embodiment, the permeation-enhancing unit 11 is used to replace the delivery unit 21, the surface of the substrate 111 forms the drug-carrying surface 210, the permeation-enhancing microunit 112 replaces the delivery microunit 212, and the drug coating 22 covers the surface of the substrate 111 and the permeation-enhancing microunit 112. That is, the permeation-enhancing unit 11 and the delivery unit 21 are combined into one.

[0064] Therefore, the drug-carrying table-type transdermal care method in the third embodiment includes the following steps: t1 moisturizing the skin of a specific area; t2 using the penetration-promoting device to drive the penetration-promoting unit to touch the skin of a specific area back and forth multiple times. Each time the skin of a specific area is touched, the drug coating is partially dissolved, and when the number of touches reaches a specific number, the drug coating is completely dissolved. The penetration-promoting micro-unit 112 in the third embodiment uses a solid microneedle needle body, which has sufficient structural strength and can puncture the skin efficiently and stably. In this third embodiment, steps s1 and s3 in the original second embodiment are combined, and the penetration-promoting micro-unit 112 punctures the skin and weakens the skin barrier while the drug coating 22 directly contacts the deep layer of the skin, so that the drug coating 22 dissolves, and the active ingredients carried are efficiently absorbed by the skin. Using the care method in the third embodiment, the user only needs to spray water on the face for moisturizing treatment, and then the care operation of weakening the skin barrier and replenishing the active ingredients can be completed by operating the penetration-promoting device in one step, and the care method is further simplified. Embodiment 4

[0065] Figure 8Schematic diagram of the structure of the penetration-enhancing unit in the fourth embodiment of the drug-carrying platform transdermal care method of the present invention. Figure 8 As shown, different from the third embodiment, in the fourth embodiment, the drug coating 22 may also only cover the penetration-promoting micro-units 112 without contacting the surface of the substrate 111. The specific process may be spraying, immersion, dripping, dispensing, etc. Embodiment 5

[0066] Fig. 9 FIG. 1 is a schematic diagram of the structure of the penetration-enhancing unit in the fifth embodiment of the drug-carrying platform transdermal care method of the present invention. Fig. 9 As shown, different from the third and fourth embodiments, in the fifth embodiment, a plurality of tips 113 are formed at the end of each penetration-promoting microunit 112. The plurality of tips 113 are combined into a cluster, and the gaps between the tips 113 form a drug storage space. Fig. 9 As shown, in the fifth embodiment, the drug coating 22 is coated on the tip 113 and the drug storage space. The tip 113 can increase the surface area of ​​the penetration-promoting microunit 112, so that the adhesion area of ​​the drug coating 22 is multiplied, thereby enhancing the bonding force between the drug coating 22 and the penetration-promoting microunit 112. At the same time, this structure can increase the drug loading capacity of the micro-protrusions and achieve large-dose drug delivery.

Claims

1. A drug-carrying table-type transdermal care method, comprising the following steps: using a permeation-promoting device to repeatedly touch the skin of a specific area to weaken the skin barrier; the permeation-promoting device comprises a permeation-promoting unit, the permeation-promoting unit having a substrate and permeation-promoting micro-units formed on the substrate; characterized in that: moisturizing the skin in the specific area where the barrier is weakened; Using a delivery device to repeatedly touch the skin of the specific area to deliver the active ingredient; The delivery device includes a delivery unit, which has a drug loading platform. A drug coating is arranged on the drug loading surface of the drug loading platform. The drug coating is water-soluble and contains the active ingredient. Each time the skin of the specific area is touched, the drug coating is partially dissolved, and when the number of touches reaches a specific number, the drug coating is completely dissolved.

2. The drug-loaded platform transdermal care method according to claim 1, characterized in that: The specific area includes at least one of the head, face, periorbital area, neck, and hands.

3. The drug-loaded platform transdermal care method according to claim 1, characterized in that: The penetration-promoting micro-unit is made of at least one of single crystal silicon, ceramics, and polymer materials.

4. The drug-loaded platform transdermal care method according to claim 3, characterized in that: The end of the penetration-promoting microunit is in a cone shape, a pyramid shape or a knife edge shape.

5. The drug-carrying platform transdermal care method according to claim 4, characterized in that: The diameter of the end of the penetration-promoting microunit is no greater than 200 nanometers.

6. The drug-loaded platform transdermal care method according to claim 1, characterized in that: The active ingredients include at least one of finasteride, minoxidil, GLP-1, insulin, semaglutide, conopeptide, tranexamic acid, hexapeptide, salicylic acid, L-vitamin C, retinoic acid, and botulinum toxin.

7. The drug-loaded platform transdermal care method according to claim 6, characterized in that: The content of finasteride is not less than 0.01% and not more than 3%.

8. The drug-carrying platform transdermal care method according to claim 6, characterized in that: The content of minoxidil is not less than 0.01% and not more than 5%.

9. The drug-loaded platform transdermal care method according to claim 1, characterized in that: The drug-carrying surface is planar.

10. The drug-carrying platform transdermal care method according to claim 1, characterized in that: The drug-carrying surface is provided with a delivery micro-unit, and the drug coating covers the drug-carrying surface and the delivery micro-unit, or the drug coating only covers the delivery micro-unit.

11. The drug-loaded platform transdermal care method according to claim 10, characterized in that: The penetration-enhancing unit is used to replace the delivery unit, the surface of the substrate forms the drug-carrying surface, the penetration-enhancing microunit replaces the delivery microunit, the drug coating covers the drug-carrying surface and the penetration-enhancing microunit, or the drug coating only covers the penetration-enhancing microunit; the drug-carrying table-type transdermal care method comprises the following steps: Apply moisturizing treatment to specific areas of skin; Using the penetration-promoting device to drive the penetration-promoting unit to repeatedly touch the skin of a specific area; Each time the skin of the specific area is touched, the drug coating is partially dissolved, and when the number of touches reaches a specific number, the drug coating is completely dissolved.

12. The drug-carrying platform transdermal care method according to claim 11, characterized in that: The end of the penetration-promoting microunit has a plurality of tips, the plurality of tips are combined into a cluster, and the drug coating is arranged in the plurality of tips and in the gaps between the tips.

13. The drug-loaded table-type transdermal care method according to any one of claims 1 to 12, characterized in that: The specific number of times is not less than 100 times and not more than 50,000 times.

Images